[1]孙 哲,杨 默,石宗华.丹参多酚酸盐与丹参酮治疗慢性心力衰竭临床研究[J].陕西中医,2019,(5):591-593.
　SUN Zhe,YANG Mo,SHI Zonghua..Clinical effect and mechanism of salvianolate and Tanshinone in the treatment of chronic heart failure[J].,2019,(5):591-593.
点击复制

丹参多酚酸盐与丹参酮治疗慢性心力衰竭临床研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2019年5期
页码:
591-593
栏目:
临床研究
出版日期:
2019-05-05

文章信息/Info

Title:
Clinical effect and mechanism of salvianolate and Tanshinone in the treatment of chronic heart failure
文章编号:
DOI:〖HT5K〗10.3969/j.issn.1000-7369.2019.05.013
作者:
孙 哲 ; 杨 默; 石宗华
郑州大学第五附属医院 (郑州 450052)
Author(s):
SUN Zhe; YANG Mo; SHI Zonghua.
Department of General Medicine,the Fifth Affiliated Hospital of Zhengzhou University（Zhengzhou 450052)
关键词:
慢性心力衰竭; 丹参酮; 丹参多酚酸盐; 疗效; 机制; 血谷丙转氨酶
Keywords:
Chronic heart failure;  Tanshinone;  Salvianolate;  Effect;  Mechanism; Serum glutamic-pyruvic transaminase
分类号:
R541.6
文献标志码:
A
摘要:
摘 要 目的:探讨丹参多酚酸盐与丹参酮治疗慢性心力衰竭患者的临床效果和机制。方法:将慢性心力衰竭患者136例作为研究对象，按照随机数字表法分为两组，每组各68例，在常规治疗的基础上研究组加用丹参酮ⅡA 进行治疗，对照组加用丹参多酚酸盐进行治疗，对比观察患者疗效。结果: 研究组治疗后临床总有效率为95.59%，明显高于对照组73.53%（P＜0.05）；治疗后两组患者CRP和Hcy水平均发生明显降低，LVEF明显升高，研究组改善程度优于对照组（P＜0.05）；两组患者头痛、眩晕、血谷丙转氨酶水平升高等不良并发症发生率分别为5.88%和8.82%，组间比较差异无统计学意义（P＞0.05），经过对症处理后消失。结论:使用丹参酮ⅡA 注射液治疗CHF的疗效优于使用丹参多酚酸盐。
Abstract:
Abstract Objective ：To investigate the clinical effect and mechanism of tanshinone and salvianolate in the treatment of chronic heart failure. Methods ：136 patients with chronic heart failure were divided into two groups according to random number table method, 68 cases in each group. On the basis of routine treatment, the study group was treated with tanshinone II A, and the control group was treated with tanshinone polyphenolic acid salt. The curative effect of the patients was compared and observed. Results ：After treatment, the total effective rate of the study group was 95.59%, which was significantly higher than that of the control group (73.53% (P< 0.05). After treatment, the levels of CRP and Hcy in the two groups decreased significantly, LVEF increased significantly, and the improvement degree of the study group was better than that of the control group (P< 0.05). The incidence of adverse complications such as headache, vertigo and elevated serum glutamic-pyruvic transaminase in the two groups was 5.88% and 8.82%, respectively. The difference was not statistically significant (P>0.05), but disappeared after symptomatic treatment. Conclusion ：Tanshinone II A injection is better than salvianolic acid salts in the treatment of CHF. The effect is remarkable.

参考文献/References:

[1] 洪玉清.丹参多酚酸盐与丹参酮ⅡA磺酸钠注射液治疗冠心病心绞痛的疗效及药物经济学比较 [J].中国医院用药评价与分析,2016,16(3):307-309.
[2] 胡文凤,王艳华,任红梅,等.应用丹参酮注射液治疗慢性心力衰竭CRP、HCY浓度变化的临床观察 [J].中医临床研究,2015,7(6):39-41.
[3] Carai M,Giancarlo C,Barbara L,et al.Hypoglycemic effects of a standardized extract of salvia miltiorrhizaroots in rats [J].Pharmacognosy Magazine, 2015,11(4): 545- 549.
[4] 罗文才,吴恒才,强永成.丹参酮ⅡA联用环磷腺苷治疗慢性心力衰竭临床疗效观察 [J].内蒙古中医药,2014,33(21):27.
[5] Cai H,Lian L,Wang Y,et al.Protective effects of Salvia miltiorrhiza injection against learning and memory impairments in streptozotocin-induced diabetic rats [J]. Experimental Therapeutic Medicine,2014,8(4):1127.
[6] 彭环庆,彭志允,谢维宁,等.基于血管内皮细胞损伤模型的丹参酮ⅡA治疗慢性心力衰竭的机制研究 [J].浙江临床医学,2015,18(3):349-351.
[7] 江其影,陈 矛,薛秋平,等.丹参酮ⅡA磺酸钠注射液对慢性心力衰竭临床疗效的观察 [J].中国实用医药,2016,11(3):121-122.
[8] Sundar D,Houreld N,Abrahamse H.The rapeutic potential and recent advances of curcumin in the treatment of aging-associated diseases [J]. Molecules, 2018,23(4):835.
[9] 刘艳霞,冯雪亚.盐酸曲美他嗪联合丹参酮ⅡA磺酸钠治疗慢性心衰临床研究 [J].内蒙古中医药,2013,32(25):33 .
[10] 薛晓岩. 米力农联合利尿剂治疗慢性肺源性心脏病严重心力衰竭疗效观察 [J]. 山西医药杂志, 2014,23(6):625-626.
[11] 高 昕. 卡维地洛与比索洛尔治疗慢性心力衰竭患者的疗效及安全性对比分析 [J]. 陕西医学杂志, 2013, 42(8):1061-1063.

相似文献/References:

[1]杨自生,金 琪,简立国.参苓养心汤治疗慢性心衰的疗效及对心功能、活动耐力、 NTProBNP、hsCRP的影响*[J].陕西中医,2019,(2):167.
　YANG Zisheng,JIN Qi,JIAN Liguo..The effect of Shenling Yangxin decoction on chronic heart failure and its effect on cardiac function，activity endurance，NTProBNP and hsCRP[J].,2019,(5):167.
[2]刘新叶,李 勇,杨东伟.盾叶冠心宁联合丹参酮治疗冠状动脉粥样硬化疗效及对患者左室功能的影响[J].陕西中医,2019,(5):584.
　LIU Xinye,LI Yong,YANG Dongwei..Effect of Dunye Guanxinning and Tanshinone on coronary atherosclerosis and left ventricular function[J].,2019,(5):584.
[3]向宗兴,拓 文,仇卫峰,等.黄芪保心汤配合西药治疗慢性心力衰竭临床研究*[J].陕西中医,2019,(8):1085.
　XIANG Zongxing,TUO Wen,QIU Weifeng,et al.Clinical value of Huangqi Baoxin decoction combined with western medicine in the treatment of chronic heart failure[J].,2019,(5):1085.
[4]尚加芬.参芪附仙饮联合盐酸曲美他嗪片辨治慢性心力衰竭心肾阳虚证临床研究[J].陕西中医,2020,(1):38.
[5]陈宗伟,沈志涛,郑振国,等.芪苈强心胶囊配合保元汤加减治疗慢性心力衰竭临床研究*[J].陕西中医,2020,(2):191.
　CHEN Zongwei,SHEN Zhitao,ZHENG Zhenguo,et al.Observation on the effect of Qili Qiangxin capsules assist Baoyuan decoction in the treatment of chronic heart failure[J].,2020,(5):191.
[6]凌 望,孙思明,王璐玲,等.温阳益气活血方改善慢性心力衰竭患者生活质量临床研究*[J].陕西中医,2020,(5):621.[doi:DOI:10.3969/j.issn.10007369.2020.05.019]
　LING Wang,SUN Siming,WANG Luling,et al.A Study on the quality of life about Wenyang Yiqi Huoxue therapy in the treatment of chronic heart failure[J].,2020,(5):621.[doi:DOI:10.3969/j.issn.10007369.2020.05.019]
[7]朱 杰,林兆奋△,胡 聃,等.中西医结合治疗慢性心力衰竭研究进展*[J].陕西中医,2020,(9):1342.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.046]
[8]刘 薇,张玉焕,李 争.芪参益气滴丸对老年气虚血瘀型心力衰竭患者心肌保护、炎症状态的影响[J].陕西中医,2021,(1):37.[doi:DOI:10.3969/j.issn.1000-7369.2020.01.008]
　LIU Wei,ZHANG Yuhuan,LI Zheng.Effects of Qishen Yiqi dropping pills on myocardial protection,inflammatory state and serum cell adhesion molecule level in elderly patients with heart failure caused by qi deficiency and blood stasis[J].,2021,(5):37.[doi:DOI:10.3969/j.issn.1000-7369.2020.01.008]
[9]黄光明.理中汤加减治疗慢性心力衰竭及对患者血清BNP、IL-10及NOS水平的影响研究[J].陕西中医,2021,(2):159.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.006]
　HUANG Guangming.Modified Lizhong decoction on clinical symptoms and levels of serum BNP,IL-10 and NOS in patients with chronic heart failure[J].,2021,(5):159.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.006]
[10]胡 芳,谭明娜,谭小娥,等.加味五苓散联合西药治疗慢性心力衰竭疗效及对患者心功能、纤维化指标、炎性因子水平的影响[J].陕西中医,2021,(2):167.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.008]
　HU Fang,TAN Mingna,TAN Xiao'e,et al.Effects of modified Wuling powder combined with western medicine on levels of cardiac function,fibrosis indicators and inflammatory factors in patients with chronic heart failure[J].,2021,(5):167.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.008]

更新日期/Last Update: 2019-05-07